Last reviewed · How we verify
FF/VI (200/25) mcg
FF/VI is a combination inhaled corticosteroid (fluticasone furoate) and long-acting beta-2 agonist (vilanterol) that reduces airway inflammation and improves bronchodilation in obstructive airway diseases.
FF/VI is a combination inhaled corticosteroid (fluticasone furoate) and long-acting beta-2 agonist (vilanterol) that reduces airway inflammation and improves bronchodilation in obstructive airway diseases. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.
At a glance
| Generic name | FF/VI (200/25) mcg |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (fluticasone furoate); Beta-2 adrenergic receptor (vilanterol) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Vilanterol is a long-acting beta-2 agonist that activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improved airflow. The combination provides both anti-inflammatory and bronchodilatory effects for sustained symptom control.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Oral candidiasis
Key clinical trials
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma (PHASE3)
- Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma (PHASE3)
- An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. (PHASE3)
- Relovair PD PK in Chinese Healthy Subjects (PHASE1)
- Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |